In a filing, BridgeBio Pharma Inc revealed its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $1.71 million on Jul 02 ’25. In the deal valued at $42.73 per share,40,000 shares were sold. As a result of this transaction, Kumar Neil now holds 955,686 shares worth roughly $44.25 million.
Then, Kumar Neil sold 40,000 shares, generating $1,701,400 in total proceeds. Upon selling the shares at $42.54, the Chief Executive Officer now owns 975,686 shares.
Before that, VIKING GLOBAL INVESTORS LP sold 3,500,000 shares. BridgeBio Pharma Inc shares valued at $154,000,000 were divested by the 10% Owner at a price of $44.00 per share. As a result of the transaction, VIKING GLOBAL INVESTORS LP now holds 18,555,375 shares, worth roughly $859.11 million.
Truist initiated its BridgeBio Pharma Inc [BBIO] rating to a Buy in a research note published on July 21, 2025; the price target was $66. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid July with a ‘”a Buy”‘ rating. Oppenheimer also remained covering BBIO and has increased its forecast on July 09, 2025 with a “an Outperform” recommendation from previously “Perform” rating. Wolfe Research started covering the stock on June 17, 2025. It rated BBIO as “an Outperform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 1.40% to $46.3. Over the last five days, the stock has lost -0.45%. BridgeBio Pharma Inc shares have risen nearly 68.42% since the year began. Nevertheless, the stocks have risen 68.73% over the past one year. While a 52-week high of $48.68 was reached on 07/14/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 45.58, which if violated will result in even more drops to 44.86. On the upside, there is a resistance level at 46.72. A further resistance level may holdings at 47.13.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-07-15, dropping by -1.64 million shares to a total of 19.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 21.12 million shares. There was a decline of -8.44%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 31, 2025 when Redburn Atlantic began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
